Kythera Biopharmaceuticals, Inc. today announced it has received authorization from Health Canada to market Belkyra “for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat (SMF) in adults.” Belkyra is a non-surgical treatment for improving the appearance and profile of submental fullness—more commonly known as “double chin,” a facial aesthetic condition that affects both women and men. Belkyra was recently launched in the U.S. under the brand name Kybela.

“We are pleased to offer Belkyra for patients who are seeking a non-surgical solution to improve the appearance of their submental fullness, sometimes referred to as a double chin, an oft-cited, but undertreated facial feature,” said Keith Leonard, President and Chief Executive Officer of Kythera Biopharmaceuticals. “The authorization of Belkyra in Canada is another milestone for Kythera and for physicians who now have a treatment for fat under the chin.”

For more details, go to: http://www.kythera.com/kythera-biopharmaceuticals-announces-health-canada-authorization-of-belkyra-a-submental-contouring-injectable-drug/